先瑞達醫療-B(06669.HK)2024年溢利5228萬元 同比增加260.9%
格隆匯3月24日丨先瑞達醫療-B(06669.HK)公告,截至2024年12月31日止年度業績,公司的收益約爲人民幣5.34億元,同比增加約12.7%。年內溢利5228萬元,同比增加260.9%;每股盈利0.17人民幣元。
於2024年,公司持續推動技術及流程的創新及迭代,在產品研發範疇方面取得重大進展。於報告期間,三款產品已完成產品定型、兩款產品正進行臨牀實驗、六款產品已向國家藥監局遞交註冊申請及七款產品已獲國家藥監局上市批準。於2024年,公司成功註冊11項專利及新提交申請16項專利。
管線研發順利進行的同時,公司的入院工作亦同步推進。截至2024年12月31日,公司的ATKDCB(膝上藥物球囊)實現1,800家醫院入院(截至2023年12月31日爲1,600家醫院);公司的BTKDCB(膝下藥物球囊)實現820家醫院入院(截至2023年12月31日爲770家醫院);公司的外周抽吸系統(AcoStream®)實現1,760家醫院入院(截至2023年12月31日爲1,300家醫院);及公司的射頻消融系統(AcoArt Cedar®)(已於2022年4月獲國家藥監局批準)實現680家醫院入院(截至2023年12月31日爲350家醫院)。該等數字預計會不斷增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.